{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '18. Posterior subcapsular cataracts or glaucoma, or any other ocular disturbances or other', 'listed related conditions (as applicable) including:', 'history of increased intraocular pressure.', 'history of retinal detachment surgery.', 'history of incisional eye surgery (other than unilateral cataract extraction or', 'laser-assisted in situ keratomileusis).', 'history of penetrating ocular trauma, severe blunt ocular trauma.', 'evidence of uveitis, iritis, or other inflammatory eye disease during screening.', 'presence of ocular herpes simplex.', '19. Known history of hypothalamic-pituitary-adrenal axis impairment.', '20. Existence of any significant surgical or medical condition, or clinically significant', 'physical finding (eg, significant nasal polyps or other clinically significant respiratory', 'tract malformations/nasal structural abnormalities, significant nasal trauma [such as nasal', 'piercing] or significant nasal septal deviation) which, in the opinion of the Investigator', \"(or in consultation with the Sponsor's medical monitor/designee), significantly interferes\", 'with the absorption, distribution, metabolism or excretion of the study medication or', \"significantly interferes with nasal air flow or interferes with the subject's ability to\", 'reliably complete the AR Assessment Diary.', '21. Participation in any investigational non-biological drug clinical study in the 30 days or', 'investigational biological drug in the 120 days preceding the Screening Visit (Visit 1)', 'or', 'planned participation in another investigational clinical study at any time during the', 'current study.', '22. Initiation of immunotherapy injections or immunosuppressive/immune-modulator', 'medications within 60 days preceding the Screening Visit (Visit 1) and/or currently', 'undergoing treatment with immunotherapy or immunosuppressive/immune-modulator', 'medications. Topical pimecrolimus cream or tacrolimus ointment treatment if initiated at', 'least 30 days prior to screening and maintained on stable dose is acceptable. A 180-day', 'washout period is required following the last dose of sublingual immunotherapy', '(investigational or other) prior to the Screening Visit (Visit 1).', '23. Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone, or', 'equivalent, within 30 days prior to the Screening Visit (Visit 1); use of a topical', 'hydrocortisone or equivalent in any concentration covering greater than 20% of the body', 'surface or the presence of an underlying condition (as judged by the Investigator) that can', 'reasonably be expected to require treatment with such preparations over the clinical study', 'duration.', '24. Previous participation in another GSP 301 NS study as a randomized subject.', '25. Clinical study participation by clinical investigator site employees and/or their immediate', 'relatives.', 'Glenmark', 'CONFIDENTIAL', 'Page 34 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '26. Study participation by more than 1 subject from the same household at the same time.', 'However, after the completion/discontinuation by 1 subject in the household, another', 'subject from the same household may be screened.', '27. Known to have failed to show symptom improvement with any approved/marketed', 'monotherapy component of the GSP 301 NS (ie, NASONEX NS, PATANASE NS, or', 'both) as judged by the Investigator.', '7.3.', 'Randomization Criteria (at the Randomization Visit (RV) - Visit 2):', '1. Continued general good health and continued eligibility according to the inclusion and', 'exclusion criteria.', '2. Has not left the known pollen area for the investigative site for 24 hours or longer during', 'the last 7 days of the placebo run-in period.', '3. No adverse event (AE) that has altered eligibility according to the inclusion and', 'exclusion criteria.', '4. Minimum 12-hour subject-reported rTNSS of an average of 6, (out of a possible 12)', 'during the last 4 days of the placebo run-in period (average of last 8 consecutive morning', '[AM] and evening [PM] assessments from the Day -4 PM assessment to the AM', 'assessment on the day of randomization).', '5. A 12-hour subject-reported reflective nasal congestion score of an average of 2 or greater', 'during the last 4 days of the placebo run-in period (average of last 8 consecutive AM and', 'PM assessments from Day -4 PM assessment to the AM assessment on the day of', 'randomization).', '6. Adequate symptom assessment diary compliance (with assistance from', 'parent/guardian/caregiver, as needed) - inadequate compliance is defined as missing one', 'or more of the entries on 2 or more assessment sessions (AM or PM) during the last 4', 'days of the placebo run-in period (during the last 8 consecutive AM and PM assessments', 'from Day -4 PM assessment to the AM assessment on the day of randomization).', '7. Adequate study medication compliance - each subject must have taken his/her single-', 'blind placebo medication (with assistance from parent/guardian/caregiver, as needed) for', 'at least 80% of the entire placebo run-in period as reported in the symptom assessment', 'diary.', '8. Absence of common cold, upper respiratory infections, otitis, lower respiratory infections', 'or acute sinusitis for 14 days prior to the Randomization Visit (Visit 2).', '9. No use of prohibited concomitant medications during the placebo run-in period.', '7.4.', 'Subject Withdrawal Criteria', 'A subject (or parent/guardian, as applicable) may voluntarily discontinue study participation at', 'any time after giving informed consent/assent and before the completion of the last visit of the', 'study. Subjects may also be withdrawn from study drug treatment at the discretion of the', 'Investigator or Sponsor for safety, noncompliance, or administrative reasons. The Investigator', 'Glenmark', 'CONFIDENTIAL', 'Page 35 of 90']\n\n###\n\n", "completion": "END"}